in professionals primarily call fluid CHF overload morning when Thank everyone. with address is to to and have leader related associated easy with We failure solutions filtration and life. Solutions’ conditions patient global the a corporate healthcare pump improve to and be second vision and of system yet failed. quality mechanical use fluid provide heart to sophisticated diuretics management earnings good quarter XXXX you, Scott update. market our with to Welcome
care length upon in patient of challenging providing the fluid management clinically technology, stay system clinically and an cost advantage readmissions may customers reduce an and reducing this assist competitive effective decongestion solution for provides in economic a readmission in population. hospital FlexFlow offers Our the our Aquadex solution proven and to of
the largest over expanded the the as by revenue with five three and of team significant XXXX, on statistics X% growth brand revenue year-over-year XX% our selected territories, of of failure our adding for scalable digit started strategy quarter and quarter We of the field of based In expand specific our growth. successful second quarters first – territories growth execution clinical specialists organization, focus pleased revenue hiring very consecutive a continuing quarter utilization our adding we adding our Aquadex result second now increase increasing achieved includes dedicated to identifying FlexFlow during the sales current heart We territories into representatives – appropriately XXXX. by currency XXXX the our marketing which sales double believe achieved are within strength to We increase QX to across increasing having with a U.S. U.S. commercialization is of team quarter of to and over a were season sales within admission hospitals Those accounts with commercial new territories XX and the territory. system the XX. our each as the accounts well the
only the but not improved sales to also where XX and team, of added team last sales made the our quality Over have our have we have existing changes months, necessary.
XX% months. As tenure in early in of a with team is their reps territories our result, for our their sales only four
months Aquadex diuretic QX, from announced and directly field team three effectively optimize failed train sales nicely focused team the use with tenure. our clinical have The experienced for in on field expanded overload, system specialist and therapy. fluid team company’s adding field to physicians force, with nurses of working who heart our patients nurses also FlexFlow As only with to complements the efforts field sales the failure we four clinical suffering
as our important With Jim the recent a Officer, Breidenstein, at sales this we changes of Chief to Commercial to not time. departure replace Jim few plan organization do we making are
Carrie Roberts Richard report Vice Powers will me. and to Sales, of Director directly President Senior of our Our Marketing,
will needed execution clinical and with to the key systems. better team our will hospital hospitals specialist These commercial organization changes adoption the In clinical report further to addition, now focus drive training to the and on marketing. align
delivery hospital larger to the integrated systems, We national access group will organizations accounts a purchasing and implementing soon be initiative networks.
The marketing the represents Annual approximately data average savings potential a have An ultrafiltration upfront impactful our despite ISPOR team costs, million reduced when The rates year delivered days resulted from $X,XXX patient our that $X,XXX Our savings over the at a to average of $X diuretics over the sales cost Conference at savings from Marketing higher period. cost per per presented costs. per hospital. per has in XX-day duration admissions healthcare average hospital analysis created versus reduced failure U.S. education readmission admission a focus hospital year. XX XXX of cost and heart The and marketing for showed of May. ISPOR with hospital was strong materials on team treated VP a of with and
partnering side, agreements international our warehousing by in we the and entering distribution Hong begin important to Italy, On progress to firm make Kong distribution logistics continue Germany. and into into Spain in international with distribution expanding
and their During to in Aquadex initial are and inventory had hospital the quarter, their product placed our that orders now customers. we Italy Asia distributors also announced supplying
We the for year to James obligate another Center allows also recently in to Solutions up the failure an Aquadex million without announced requiring purchase per the VAMC Medical Tampa fluid to to VA setting FlexFlow to the provides awarded a up the CHF to the year A. blanket up million Department in Florida. managing services option not Aquadex does purchase system Affairs an of agreement an from Haley in system is supply X the inventory $X.X and blanket the at patients agreement The period admission Tampa purchases outpatient but expansion purchase us. with $X.X VA for Tampa, to in use with outpatient heart Veterans to This for hospital.
sales growth department of excess ourselves Given provider position from our expanded in fluid accelerated to remove therapy by anticipate when cardiologists, worldwide emergency continuing their and we for intensivists the market fluid of hospitalists, physicians overload failed. as diuretics commercialization the have efforts, patients ultrafiltration to primary
offering when to utilization guiding assist for will and Aquadex will We assist valuable will have and to diagnostic and believe We opportunities patient which in system. early stop provide overloaded to to and a our important therapy, in identification a several that in capabilities tool physicians quicker pursuing determining monitoring therapy diagnostic our the help in capability a increase start ultrafiltration. provide of our system Aquadex provide tool when clinicians it nurses an by of fluid the to been adoption accompany this allow
to expect soon. this news on front further We have
the Following confidentially marketed spearheading quarter, a proceeds of we at faced offering public awareness the the management million growing current of the challenges end have raise in stock. our failed the turn QX gross an only healthcare can over CHF expense and financial forefront fluid when diuretic of the therapy thereby as common walk in additional to clinical diuretics of $X.X be system. results with heart failure the of reduce outcomes, continues Solutions and treatment opportunity and improve through major using ultrafiltration an our value the of Claudia to to introducing will details. you reduce I hospitalization now rates to a who IV call
I comments that, some to will open Following the provide call will and questions. closing
